Loading...
Market
How many countries will have approved ZyVac TCV by end of 2025?
2
Resolution / Starting Odds
Less than 10 countries • 25%
10 to 20 countries • 25%
21 to 30 countries • 25%
More than 30 countries • 25%
Official health ministry announcements and regulatory databases
Story
Zydus Lifesciences' ZyVac TCV Typhoid Vaccine Gets WHO Approval
Oct 23, 2024, 05:24 AM
Zydus Lifesciences Ltd announced on Wednesday that its Typhoid Vi conjugate vaccine, ZyVac TCV, has received in-principle approval from the World Health Organization (WHO). This prequalification marks a significant step for the company in addressing typhoid, a serious infectious disease. The WHO prequalification is essential for global health initiatives as it ensures the vaccine meets international standards for quality, safety, and efficacy. This approval will potentially enhance Zydus Lifesciences' market reach and contribute to global efforts in combating typhoid.
View original story
Similar markets
Less than 5 • 25%
5 to 10 • 25%
11 to 15 • 25%
More than 15 • 25%
1-5 • 25%
6-10 • 25%
11-15 • 25%
More than 15 • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
No countries • 25%
1 to 5 countries • 25%
6 to 10 countries • 25%
More than 10 countries • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
0-10 countries • 25%
11-20 countries • 25%
21-30 countries • 25%
More than 30 countries • 25%
Approved in all major markets • 25%
Approved in some major markets • 25%
Not approved in any major markets • 25%
Approval status pending • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61-120 • 25%
Less than 5 • 33%
5 to 10 • 34%
More than 10 • 33%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
16+ countries • 25%
Less than 5 • 25%
5 to 10 • 25%
11 to 20 • 25%
More than 20 • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Less than 20 countries • 25%
20 to 40 countries • 25%
41 to 60 countries • 25%
More than 60 countries • 25%